Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

Recruiting

Phase 2

LeuprolideStudy to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

Sponsor:

Enteris BioPharma Inc.

Code:

NCT05096065

Conditions

Endometriosis

Eligibility Criteria

Sex: Female

Age: 18 - 49

Healthy Volunteers: Not accepted

Interventions

Leuprolide Oral Tablet - 120 mg - QD- Treatment A

Leuprolide Oral Tablet - 80 mg - QD - Treatment B

Leuprolide Oral Tablet - 60 mg - QD - Treatment C

Leuprolide Oral Tablet - 60 mg - BID - Treatment D

Leuprolide Oral Tablet - 40 mg - BID - Treatment E

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-24. This information was provided to ClinicalTrials.gov by Enteris BioPharma Inc. on 2022-03-22.